Markets:

Overview

News

Currencies

International

Treasuries

Aclaris Therapeutics, Inc. - Common Stock (NQ:ACRS)

3.771 -0.019 (-0.50%)

Delayed Quote Updated: 1:47 PM EDT, Oct 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Aclaris Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Aclaris Therapeutics ATI-052 Posts Early Eczema, Asthma Signals in Phase 1b ↗

October 27, 2026

Aclaris Therapeutics (NASDAQ:ACRS) reported Phase 1b proof-of-concept results for ATI-052, its bispecific antibody designed to inhibit thymic stromal lymphopoietin (TSLP) and IL-4 receptor alpha, in...

Via MarketBeat

What's going on in today's after hours session ↗

September 14, 2026

Via Chartmill

Wondering what's happening in today's after-hours session? ↗

June 30, 2026

Via Chartmill

3 Penny Stocks Under $5 Backed by Real Revenue Growth ↗

June 20, 2026

These three penny stocks under $5 generate real revenue and have catalysts that analysts believe could drive significant upside

Via MarketBeat

Aclaris Therapeutics Maps Busy Pipeline Calendar, Plans Phase 2 Asthma Trial for ATI-052 ↗

June 04, 2026

Aclaris Therapeutics (NASDAQ:ACRS) executives outlined a busy clinical calendar for the biotechnology company during a fireside chat at the Jefferies 2026 Global Healthcare Conference, highlighting...

Via MarketBeat

CarMax Stock Down 47% This Past Year, But One Fund Is Betting $6 Million on a Turnaround ↗

February 03, 2026

CarMax runs a nationwide network of used car stores and digital channels, offering multi-channel sales and financing to U.S. consumers.

Via The Motley Fool

Topics Regulatory Compliance

Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter. ↗

February 03, 2026

This clinical-stage biotech develops therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition.

Via The Motley Fool

Here are the top movers in Tuesday's session. ↗

January 20, 2026

Via Chartmill

Tuesday's session: top gainers and losers ↗

January 20, 2026

Via Chartmill

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

January 20, 2026

Via Chartmill

Stock Market Today: US Future Edge Higher Ahead Of FOMC Decision—Meta, Microsoft Earnings In Focus ↗

July 30, 2025

U.S. stock futures rose on Wednesday after ending lower on Tuesday. Futures of major benchmark indices were slightly higher.

Via Benzinga

Aclaris Therapeutics Stock Spikes In After‑Hours Session Following Major Announcement ↗

July 30, 2025

Aclaris Therapeutics Inc (NASDAQ: ACRS) surgged 21.94% in after-hours trading on Tuesday after positive top-line results from its open-label Phase 2a trial.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

July 29, 2025

Via Benzinga

What's going on in today's after hours session ↗

July 29, 2025

Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

May 28, 2025

Via Benzinga

This Arista Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

May 28, 2025

Via Benzinga

Aclaris Stock Rises As Analyst Projects Billions In Sales For New Therapy ↗

December 23, 2024

HC Wainwright upgraded Aclaris Therapeutics (ACRS) to Buy with a $20 price target. Aclaris gains after licensing agreement with Biosion for potential best-in-class therapies for atopic dermatitis and...

Via Benzinga

Santa Rally, January Effect, And Top Stock Picks ↗

December 23, 2024

Explore December 23's top pre-market picks, macro insights, and Santa Rally opportunities with StoryTrading's 4-pillar strategy. Join the community for exclusive trade ideas!

Via Talk Markets

Topics Stocks / Equities

This Weyerhaeuser Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday ↗

December 23, 2024

Via Benzinga

Level Up Your Trading: Inside The 4-Pillar Strategy Behind Triple-Digit Returns ↗

December 18, 2024

Explore market insights and top picks with our 4-pillar strategy.

Via Talk Markets

Topics Stocks / Equities

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 19, 2024

Via Benzinga

Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments ↗

November 19, 2024

Aclaris secures global rights to Biosion's BSI-045B, advancing trials for atopic dermatitis, asthma, and more. Stock surges on promising updates.

Via Benzinga

War, Gold, And Opportunity: Uncovering Today’s Market Moves ↗

November 19, 2024

Geopolitical tensions drive market moves as we analyze top picks.

Via Talk Markets

This BioNTech Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗

November 19, 2024

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

October 28, 2024

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

October 25, 2024

Via Benzinga

Aclaris Therapeutics And 3 Other Stocks Under $2 Insiders Are Buying ↗

July 23, 2024

Via Benzinga

3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices

July 11, 2024

Beaten-down stocks offer value to investors, but not all are worth buying. This is a look at three biopharma at long-term lows with catalysts for higher prices.

Via MarketBeat

Aclaris Therapeutics And 1 Other Stock Under $5 Insiders Are Buying ↗

July 08, 2024

Via Benzinga

$1.8M Bet On This Health Care Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying ↗

June 14, 2024

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.